well_027e,sel_plate,sel_well,expt,selection,category,antigen,genotype_pair,genotype_CS,background_CS,strain_CS,loc_CS,cond_CS,genotype_S,background_S,strain_S,loc_S,cond_S,cond_notes,bflm,swim,twitch,swarm,PMB-R,FEP-R,TET-R,CIP-R,CHL-R,GEN-R,ERY-R,IPM-R,cdiGMP,FliC,FliCa,FliCb,FlgEHKL,PilQ,PilA,PilB,LasA,LasB,Apr,XcpQ,ToxA,EstA,LepA,PlpD,Phz,Pcn,Pvd,Hcn,Rhl,T3SS,T6SS,Pel,Psl,CdrB,SCV,Mucoid,Alginate,OprM,OprJ,OprN,OprOP,OpdH,OprD,OprL,OprF,OprG,OprH,OprB,MexAB,MexCD,MexEF,MexJK,MexXY,MexGHI,PirA,Pfu,TonB,FptA,FpvA,PfeA,CupB5,CupA,CupB,CupC,CupD,LPS-LipidA-Palmitoyl,L-LipidA-Ara4N,LPS-CPA,LPS-OSA,LPS-galU,LPS-rough,LPS
E9,1,A1,027i,1.A1,QS,pleotropic,lasR/WT,∆lasR,PA14,1264,,stationary,WT,PA14,430,,stationary,"LasR is a major QS response regulator; LasR binds the HSL QS signal OdDHL (aka PAI) and transcriptionally activates virulence factors LasA protease, LasB elastase, Apr alkaline protease, ToxA; LasR/OdDHL also activates other QS systems: IqsRI, RhlRI, PqsRABCD [@Lee:2015bh]",,,,,,,,,,,,,,,,,,,,,1.0,1.0,1.0,1.0,1.0,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
E10,1,A2,027i,1.A2,QS,pleotropic,WT/lasR,WT,PA14,430,,stationary,∆lasR,PA14,1264,,stationary,"LasR is a major QS response regulator; LasR binds the HSL QS signal OdDHL (aka PAI) and transcriptionally activates virulence factors LasA protease, LasB elastase, Apr alkaline protease; LasR/OdDHL also activates other QS systems: IqsRI, RhlRI, PqsRABCD [@Lee:2015bh]",,,,,,,,,,,,,,,,,,,,,-1.0,-1.0,-1.0,-1.0,-1.0,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
E11,1,A3,027i,1.A3,QS,pleotropic,rhlR/WT,rhlR::Tn,PA14,NR_37943,No grow 3	G9,stationary,WT,PA14,430,,stationary,"RhlR is a major QS response regulator; RhlR binds the HSL QS signal BHL and activates LasB elastase, RhlAB rhamnolipids, Phz pyocyanin, Hcn hydrogen cyanide synthase[@Lee:2015bh]",,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,1.0,1.0,,1.0,1.0,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
F1,1,A4,027i,1.A4,QS,pleotropic,WT/rhlR,WT,PA14,430,,stationary,rhlR::Tn,PA14,NR_37943,No grow 3	G9,stationary,"RhlR is a major QS response regulator; RhlR binds the HSL QS signal BHL and activates LasB elastase, RhlAB rhamnolipids, Phz pyocyanin, Hcn hydrogen cyanide synthase[@Lee:2015bh]",,,,,,,,,,,,,,,,,,,,,,-1.0,,,,,,,-1.0,-1.0,,-1.0,-1.0,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
E12,1,A5,027i,1.A5,QS,pleotropic,qscR/WT,qscR::Tn,PA14,NR_42798,10-3	E8,stationary,WT,PA14,430,,stationary,"QscR is an anti-activator of LasR; forms complexes with LasR/OdDHL (PAI) and RhlR/BHL, reducing their transcriptional activity. QscR/OdDHL also activates its own regulon. [@Lee:2015bh]",,,,,,,,,,,,,,,,,,,,,-1.0,-1.0,-1.0,,-1.0,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
F2,1,A6,027i,1.A6,QS,pleotropic,WT/qscR,WT,PA14,430,,stationary,qscR::Tn,PA14,NR_42798,10-3	E8,stationary,"QscR is an anti-activator of LasR; forms complexes with LasR/OdDHL (PAI) and RhlR/BHL, reducing their transcriptional activity. QscR/OdDHL also activates its own regulon. [@Lee:2015bh]",,,,,,,,,,,,,,,,,,,,,1.0,1.0,1.0,,1.0,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,A7,027i,1.A7,secretion,T2SS secreton and products,xcpQ/WT,xcpQ::Tn,PA14,NR_26075,2-2	H7,stationary,WT,PA14,430,,stationary,"XcpQ is the secretin for the Xcp T2SS; Xcp secretes: chitin binding protein CbpD, protein-elastase LasA and LasB, lipases LipA and LipC, lipooxygenase LoxA, aminopeptidase PaAP, alkaline phosphatase PhoA; phospholipases PlcB, PlcH, PlcN; protease PmpA, protease PrpL, and ToxA [@Filloux:2011dl]. Xcp is induced by LasR, e.g. in stationary phase [@ChaponHerve:1997il] ",,,,,,,,,,,,,,,,,,,,,1.0,1.0,,1.0,1.0,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,A8,027i,1.A8,secretion,T2SS secreton and products,xcpQ/WT,xcpQ::Tn,PA14,NR_41108,9-3	H12,stationary,WT,PA14,430,,stationary,see 1-A7,,,,,,,,,,,,,,,,,,,,,1.0,1.0,,1.0,1.0,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,A9,027i,1.A9,secretion,T2SS secreton,xcpQ/xcpR,xcpQ::Tn,PA14,NR_26075,2-2	H7,stationary,xcpR::Tn,PA14,NR_48371,12-3	C4,stationary,"XcpR is the ATPase for the Xcp T2SS [@Douzi:2012bv], necessary for translocation of products but not for assembly of secretin at OM",,,,,,,,,,,,,,,,,,,,,-1.0,-1.0,,1.0,-1.0,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,A10,027i,1.A10,secretion,T2SS secreton,xcpQ/xcpR,xcpQ::Tn,PA14,NR_41108,9-3	H12,stationary,xcpR::Tn,PA14,NR_48371,12-3	C4,stationary,see 1-A9,,,,,,,,,,,,,,,,,,,,,-1.0,-1.0,,1.0,-1.0,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
G11,1,A11,027i,1.A11,iron,pleotropic,pvdS/WT,pvdS::Tn,PA14,NR_34241,6-2	G5,stationary,WT,PA14,430,,stationary,"PvdS is an ECFσ-factor, induces transcription of ~80 genes [@Schulz:2015cm], inc. T3SS (exsA, exoT), Exotoxin A (toxR/regA), PrpL protase, and pyoveridine biosynthesis; regulation: Fe-pvd complexes bind OM transporter FpvA, causes cleavage of periplasmic anti-activator FpvR, which releases PvdS and FpvI [@Chevalier:2019fe]",,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,1.0,,,1.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
G12,1,A12,027i,1.A12,iron,pyoverdine,pvdA/WT,pvdA::Tn,PA14,NR_30448,4-3	H6,stationary,WT,PA14,430,,stationary,"PvdA is an N-hydroxylating flavoprotein monoxygenase (NMO), critical for pyoverdine biosynthesis [@Olucha:2011fm]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
H8,1,B1,027i,1.B1,regulator,pleotropic,SA113/ladS,,SA113,,,scrape,ladS#PA14_19340::Tn,PA14,NR_29763,4-2	D6,scrape,"LadS antagonizes RetS, downregulating Psl/Psl and upregulating T3SS [@Mikkelsen:2011ika]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
B7,1,B2,027i,1.B2,general,Pa,SA113/WT,,SA113,,,scrape,WT,PAK,517,,scrape,,,,,,,,,,,,,,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,,1.0,,,,,,,,,,1.0,0.0,1.0,1.0,,,,,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,,,,,,,,1.0,,,,1.0,1.0,1.0,1.0,1.0,,,1.0,1.0,,,1.0
,1,B3,027i,1.B3,general,Pa,SA113/WT,,SA113,,,scrape,WT,PAO1,220,,scrape,,,,,,,,,,,,,,1.0,1.0,,1.0,1.0,1.0,1.0,1.0,1.0,1.0,,1.0,,,,,,,,,,1.0,0.0,1.0,1.0,,,,,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,,,,,,,,1.0,,,,1.0,1.0,1.0,1.0,1.0,,,1.0,1.0,,,1.0
,1,B4,027i,1.B4,general,Pa,SA113/WT,,SA113,,,scrape,WT,PA103,209,,scrape,,,,,,,,,,,,,,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,,1.0,,,,,,,,,,1.0,0.0,0.0,0.0,,,,,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,,,,,,,,1.0,,,,1.0,1.0,1.0,1.0,1.0,,,1.0,1.0,,,1.0
B8,1,B5,027i,1.B5,general,Pa,SA113/WT,,SA113,,,scrape,WT,PA14,430,,scrape,,,,,,,,,,,,,,1.0,1.0,,1.0,1.0,1.0,1.0,1.0,1.0,1.0,,1.0,,,,,,,,,,1.0,0.0,1.0,0.0,,,,,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,,,,,,,,1.0,,,,1.0,1.0,1.0,1.0,1.0,,,0.0,1.0,,,1.0
B8,1,B6,027i,1.B6,general,Pa,SA113/WT,,SA113,,,scrape,WT,PA14,430,,scrape,,,,,,,,,,,,,,1.0,1.0,,1.0,1.0,1.0,1.0,1.0,1.0,1.0,,1.0,,,,,,,,,,1.0,0.0,1.0,0.0,,,,,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,,,,,,,,1.0,,,,1.0,1.0,1.0,1.0,1.0,,,0.0,1.0,,,1.0
B8,1,B7,027i,1.B7,general,Pa,SA113/WT,,SA113,,,scrape,WT,PA14,430,,scrape,,,,,,,,,,,,,,1.0,1.0,,1.0,1.0,1.0,1.0,1.0,1.0,1.0,,1.0,,,,,,,,,,1.0,0.0,1.0,0.0,,,,,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,,,,,,,,1.0,,,,1.0,1.0,1.0,1.0,1.0,,,0.0,1.0,,,1.0
F3,1,B8,027i,1.B8,EPS,Pel,pelA/WT,pelA::Tn,PA14,NR_26187,2-3	B10,scrape,WT,PA14,430,,scrape,Extracellular polysaccharide Pel,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,B9,027i,1.B9,EPS,CdrB,cdrB/WT,cdrB#PA14_61190::Tn,PA14,NR_45954,11-4	D6,scrape,WT,PA14,430,,scrape,CdrB is the transporter/TpsB component of a T5bSS (two-partner) transporter (TpsA = CdrA) [@Borlee:2010em] [@Filloux:2011dl],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
F4,1,B10,027i,1.B10,EPS,CdrA,cdrA/WT,cdrA#PA14_61200::Tn,PA14,NR_37866,8-1	F4,scrape,WT,PA14,430,,scrape,"CdrA is the passenger/TpsA component of a T5bSS (two-partner) transporter (TpsB= CdrB); c-di-GMP-regulated; adhesin, psl-binding lectin [@Borlee:2010em] [@Filloux:2011dl]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
F10,1,B11,027i,1.B11,c-di-GMP,???,wspA/WT,wspA#PA14_08450::Tn,PA14,NR_23967,1-2	G11,scrape,WT,PA14,430,,scrape,WspA is part of the Wsp phosphorelay system contributing to autoaggregation. wspA mutants probably have low c-di-GMP and cannot form SCV [@DArgenio:2002ff],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
F11,1,B12,027i,1.B12,c-di-GMP,???,wspE/WT,wspE#PA14_16470::Tn,PA14,NR_25862,2-2	C11,scrape,WT,PA14,430,,scrape,WspE is part of the Wsp phosphorelay system contributing to autoaggregation. wspE mutants probably have low c-di-GMP and cannot form SCV [@DArgenio:2002ff],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
E8,1,C1,027i,1.C1,alginate,alginate,algU/WT,algU::Tn,PA14,NR_40799,9-3	C3,scrape,WT,PA14,430,,scrape,"AlgU is a major ECFσ-factor which regulates stress responses, virulence factors, and alginate production (overproduction yielding the mucoid phenotype) [@Chevalier:2019fe]. AlgU regulon has been characterized by transcriptomics [@Schulz:2015cm]. PAO1 algU mutants are defective in Psl production [@Bazire:2010gt].",,,,,,,,,,,,,,1.0,,,1.0,,,,,,,,,,,,,,,,,,,0.0,0.0,,,,1.0,,,,,,1.0,,,,,,1.0,,,,,,,,,,,,,1.0,,,,,,,,,,
,1,C2,027i,1.C2,alginate,mucoid,WT/mucB,WT,PA14,430,,scrape,mucB::Tn,PA14,NR_25615,2-1	G6,scrape,"MucB is a negative regulator of AlgU; MucB stabilizes MucA in the periplasm, preventing its degradation and prolonging its repression of AlgU [@Chevalier:2019fe]. mucB deletions confer a mucoidy phenotype [@Schurr:1996bh]. AlgU regulon has been characterized by transcriptomics; algU overexpression represses fleQ and fliC transcription, though other HBB genes are equivocal [@Schulz:2015cm].",,,,,,,,,,,,,,-1.0,,,-1.0,,,,,,,,,,,,,,,,,,,0.0,0.0,,,1.0,1.0,,,,,,-1.0,,,,,,-1.0,,,,,,,,,,,,,,,,,,,,,,,
G8,1,C3,027i,1.C3,alginate,mucoid,WT/mucB,WT,PA14,430,,scrape,mucB::Tn,PA14,NR_25615,2-1	G6,scrape,see 1-C2,,,,,,,,,,,,,,-1.0,,,-1.0,,,,,,,,,,,,,,,,,,,,0.0,,,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
E7,1,C4,027i,1.C4,alginate,alginate,WT/dsbM,WT,PA14,430,,scrape,dsbM#PA14_00700::Tn,PA14,NR_27274,3-1	B6,scrape,"deletion of homolog in PAO1 → increased algU expression (Wood & Ohman, mBio 2012)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,C5,027i,1.C5,alginate,alginate,WT/mucD,WT,PA14,430,,scrape,mucD::Tn,PA14,NR_34714,6-3	F7,scrape,"MucD is a protease; loss results in alginate overexpression, independently of AlgW [@Damron:2011ed] [@Damron:2012kd]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,C6,027i,1.C6,biofilm,biofilm,WT/bfiR,WT,PA14,430,,scrape,bfiR#PA14_09690::Tn,PA14,NR_28988,3-4	F6,scrape,BfiSR TCS necessary for biofilm initiation and maturation [@Petrova:2010gh],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
F8,1,C7,027i,1.C7,c-di-GMP,SCV,WT/yfiR,WT,PA14,430,,scrape,yfiR#PA14_49880::Tn,PA14,NR_52922,12-4	D11,scrape,"YfiN is a membrane-bound diguanylate cyclase (DGC), regulated by YfiR; yfiR mutation causes SCV phenotype in PAO1 [@Malone:2010ew]. SCVs are generally nonmotile, hyperpiliated, and overproduce Pel and Psl [@Malone:2015cva] ",1.0,-1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,0.0,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,C8,027i,1.C8,c-di-GMP,SCV,fimX/yfiR fimX,∆fimX#PA4959,PA103,23,,scrape,∆fimX yfiR#PA1121::Tn.2(Tc),,590,,scrape,SCV phenotype; Identified in fimX suppressor screen  [@Jain:2012ica]. (FimX is required for T4P assembly under low c-di-GMP conditions; fimX mutation here only due to convenience),1.0,-1.0,1.0,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,C9,027i,1.C9,c-di-GMP,SCV,fimX/PA0171 fimX,∆fimX#PA4959,PA103,23,,scrape,∆fimX PA0171::Tn.12(Tc),PA103,591,,scrape,see 1-C8,1.0,-1.0,1.0,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,C10,027i,1.C10,efflux,MexAB-OprM,oprM/rocA2,oprM::Tn,PA14,NR_38915,8-3	D1,scrape,rocA2#PA14_24710::Tn,PA14,NR_26984,12-4	H2,scrape,RocA2 is response regulator to RocS2 (together known as Roc2 TCS); RocA2 downregulates MexAB-OprM in biofilms for unknown reasons; crosstalk w/ cupC regulation [@Mikkelsen:2011ika],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,,,,,1.0,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,
F5,1,C11,027i,1.C11,EPS,Pel,pel/WT,∆pel,PAO1 Parsek,1257,,scrape,WT,PAO1 Parsek,1256,,scrape,Deficient in extracellular polysaccharide Pel biosynthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
F6,1,C12,027i,1.C12,EPS,Psl,psl/WT,∆psl,PAO1 Parsek,1258,,scrape,WT,PAO1 Parsek,1256,,scrape,Deficient in extracellular polysaccharide Psl biosynthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
F7,1,D1,027i,1.D1,EPS,Pel/Psl,pel-psl/WT,∆pel ∆psl,PAO1 Parsek,1259,,scrape,WT,PAO1 Parsek,1256,,scrape,Deficient in extracellular polysaccharide Pel and Psl biosynthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,D2,027i,1.D2,motility,T4P,pilA/WT,∆pilA,PAO1,311,,scrape,WT,PAO1,220,,scrape,,,,,,,,,,,,,,,,,,,0.0,1.0,,,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,D3,027i,1.D3,motility,T4P,pilA/WT,∆pilA::gmR,PAK,380,,scrape,WT,PAK,517,,scrape,,,,,,,,,,,,,,,,,,,0.0,1.0,,,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,D4,027i,1.D4,motility,T4P,fliC pilA/fliC,∆fliC ∆pilA,PAO1,501,,scrape,∆fliC::TcR,PAO1,298,,scrape,unscarred mutant from #312,,,,,,,,,,,,,,0.0,,,-1.0,,1.0,,,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,D5,027i,1.D5,motility,T4P,fliC pilA/fliC,∆fliC ∆pilA,PAO1,1112,,scrape,∆fliC::TcR,PAO1,298,,scrape,,,,,,,,,,,,,,,0.0,,,0.0,,1.0,,,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,D6,027i,1.D6,motility,T4P,pilA/WT,∆pilA,PA103,213,,scrape,WT,PA103,209,,scrape,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,1.0,,,,,,,,,,,,,,,,,0.0,0.0,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,D7,027i,1.D7,porin,PilQ,pilQ/pilA,∆pilQ,PAO1,1052,,scrape,∆pilA,PAO1,311,,scrape,,,,,,,,,,,,,,,,,,,1.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,D8,027i,1.D8,porin,PilQ,pilQ/pilA,∆pilQ,PAO1,1052,,scrape,∆pilA,PAO1,311,,scrape,,,,,,,,,,,,,,,,,,,1.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,D9,027i,1.D9,porin,PilQ,pilQ/pilA,∆pilQ,PAO1,1052,,scrape,∆pilA,PAO1,311,,scrape,,,,,,,,,,,,,,,,,,,1.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,D10,027i,1.D10,porin,PilQ,pilQ/pilA,∆pilQ,PA103,1053,,scrape,∆pilA::gmR,PA103,213,,scrape,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,1.0,0.0,,,,,,,,,,,,,,,,,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,D11,027i,1.D11,porin,PilQ,pilQ/pilB,pilQ::Tn,PA14,NR_41699,10-1	D5,scrape,pilB::Tn,PA14,NR_56672,15-3	H1,scrape,,,,,,,,,,,,,,,,,,,1.0,,-1.0,,,,,,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,D12,027i,1.D12,secretion,T6SS,gacA/retS,gacA::Tn(GmR) fliC::TcR ∆pilA,PAO1,Tom#220,,scrape,retS::Tn(GmR) fliC::TcR ∆pilA,PAO1,Tom#223,,scrape,"retS mutant should overexpress Pel/Psl and T6SS like a ""chronic"" isolate, while gacA mutant should be pro-motility and express T3SS. RetS inhibits GacAS. GacAS activate RsmY/RsmZ which inhibit RsmA and promote motility, T3SS activation while inhibiting Pel/Psl and T6SS [@Mikkelsen:2011ika]. gacA mutants have increased swimming and twitching motility vs. WT [@Wei:2013jn]. retS mutants have decreased transcription of T4P-related genes including pilQ [@Goodman:2004bw]. gacA and gacS mutations are phenotypically identical. These mutants were identified by screening a non-arrayed transposon library and sequencing inserts [@Murray:2008cs]. Both strains carry pUCP-SK plasmid, but I will grow w/o abx. ",,,,,,,,,,,,,,0.0,,,-1.0,-1.0,0.0,,,,,,,,,,,,,,,-1.0,1.0,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,E1,027i,1.E1,efflux,MexAB-OprM,efflux/↑mexAB,"(mPMQ72) ∆exsD attB::PexoT::ZTP_lacZ ∆{mexAB,oprM} +nfxB ∆{mexCD,oprJ} ∆mexJKL ∆mexXY ∆opmH362 ∆{mexEF,oprN}",PAO1 PA0397,,,gm15+ara0.2%,"(mPMQ72 +mexAB +oprM) ∆exsD attB::PexoT::ZTP_lacZ ∆{mexAB,oprM} +nfxB ∆{mexCD,oprJ} ∆mexJKL ∆mexXY ∆opmH362 ∆{mexEF,oprN}",PAO1 PA0397,,,gm15+ara0.2%,single efflux system overexpression in trans; CS = PA0397 [@Chuanchuen:2005gy] ∆exsD w/ ZTP riboswitch reporter in attB site + empty vector; vector confers Gm15 resistance,,,,,,1.0,1.0,1.0,,0.0,,,,0.0,,,0.0,,0.0,0.0,,,,,,,,,,,,,,0.0,,,,,,,,1.0,0.0,0.0,,,,,,,,,1.0,0.0,0.0,0.0,0.0,,,,,,,,,,,,,,,,,,,
,1,E2,027i,1.E2,efflux,MexCD-OprJ,efflux/↑mexCD,"(mPMQ72) ∆exsD attB::PexoT::ZTP_lacZ ∆{mexAB,oprM} +nfxB ∆{mexCD,oprJ} ∆mexJKL ∆mexXY ∆opmH362 ∆{mexEF,oprN}",PAO1 PA0397,,,gm15+ara0.2%,"(mPMQ72 +mexCD +oprJ) ∆exsD attB::PexoT::ZTP_lacZ ∆{mexAB,oprM} +nfxB ∆{mexCD,oprJ} ∆mexJKL ∆mexXY ∆opmH362 ∆{mexEF,oprN}",PAO1 PA0397,,,gm15+ara0.2%,single efflux system overexpression in trans; CS = PA0397 [@Chuanchuen:2005gy] ∆exsD w/ ZTP riboswitch reporter in attB site + empty vector; vector confers Gm15 resistance,,,,,,1.0,,1.0,1.0,0.0,1.0,,,0.0,,,0.0,,0.0,0.0,,,,,,,,,,,,,,0.0,,,,,,,,0.0,1.0,0.0,,,,,,,,,0.0,1.0,0.0,0.0,0.0,,,,,,,,,,,,,,,,,,,
,1,E3,027i,1.E3,efflux,MexEF-OprN,efflux/↑mexEF,"(mPMQ72) ∆exsD attB::PexoT::ZTP_lacZ ∆{mexAB,oprM} +nfxB ∆{mexCD,oprJ} ∆mexJKL ∆mexXY ∆opmH362 ∆{mexEF,oprN}",PAO1 PA0397,,,gm15+ara0.2%,"(mPMQ72 +mexEF +oprN) ∆exsD attB::PexoT::ZTP_lacZ ∆{mexAB,oprM} +nfxB ∆{mexCD,oprJ} ∆mexJKL ∆mexXY ∆opmH362 ∆{mexEF,oprN}",PAO1 PA0397,,,gm15+ara0.2%,single efflux system overexpression in trans; CS = PA0397 [@Chuanchuen:2005gy] ∆exsD w/ ZTP riboswitch reporter in attB site + empty vector; vector confers Gm15 resistance,,,,,,,1.0,1.0,1.0,0.0,,,,0.0,,,0.0,,0.0,0.0,,,,,,,,,,,,,,0.0,,,,,,,,0.0,0.0,1.0,,,,,,,,,0.0,0.0,1.0,0.0,0.0,,,,,,,,,,,,,,,,,,,
,1,E4,027i,1.E4,efflux,MexJK-OprM,efflux/↑mexJK,"(mPMQ72) ∆exsD attB::PexoT::ZTP_lacZ ∆{mexAB,oprM} +nfxB ∆{mexCD,oprJ} ∆mexJKL ∆mexXY ∆opmH362 ∆{mexEF,oprN}",PAO1 PA0397,,,gm15+ara0.2%,"(mPMQ72 +mexJK +oprM) ∆exsD attB::PexoT::ZTP_lacZ ∆{mexAB,oprM} +nfxB ∆{mexCD,oprJ} ∆mexJKL ∆mexXY ∆opmH362 ∆{mexEF,oprN}",PAO1 PA0397,,,gm15+ara0.2%,single efflux system overexpression in trans; CS = PA0397 [@Chuanchuen:2005gy] ∆exsD w/ ZTP riboswitch reporter in attB site + empty vector; vector confers Gm15 resistance,,,,,,1.0,1.0,0.0,1.0,-1.0,1.0,,,0.0,,,0.0,,0.0,0.0,,,,,,,,,,,,,,0.0,,,,,,,,1.0,0.0,0.0,,,,,,,,,0.0,0.0,0.0,1.0,0.0,,,,,,,,,,,,,,,,,,,
,1,E5,027i,1.E5,efflux,MexXY-OprM,efflux/↑mexXY,"(mPMQ72) ∆exsD attB::PexoT::ZTP_lacZ ∆{mexAB,oprM} +nfxB ∆{mexCD,oprJ} ∆mexJKL ∆mexXY ∆opmH362 ∆{mexEF,oprN}",PAO1 PA0397,,,gm15+ara0.02%,"(mPMQ72 +mexXY +oprM) ∆exsD attB::PexoT::ZTP_lacZ ∆{mexAB,oprM} +nfxB ∆{mexCD,oprJ} ∆mexJKL ∆mexXY ∆opmH362 ∆{mexEF,oprN}",PAO1 PA0397,,,gm15+ara0.02%,single efflux system overexpression in trans; CS = PA0397 [@Chuanchuen:2005gy] ∆exsD w/ ZTP riboswitch reporter in attB site + empty vector; vector confers Gm15 resistance,,,,,,,1.0,1.0,,1.0,1.0,,,0.0,,,0.0,,0.0,0.0,,,,,,,,,,,,,,0.0,,,,,,,,1.0,0.0,0.0,,,,,,,,,0.0,0.0,0.0,0.0,1.0,,,,,,,,,,,,,,,,,,,
,1,E6,027i,1.E6,secretion,T3SS,exsA/↑ExsA,∆exsA (pMMB67EH),PA14,1555,,cb200+IPTG,∆exsA (pMMB67EH pTac::exsA),PA14,1557,,cb200+IPTG,IPTG-inducible T3SS activation; pTac::exsA made by Deanna during rotation. Very leaky (OK for me),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,E7,027i,1.E7,porin,OprP,oprP/WT,oprP::Tn,PA14,NR_44863,No grow 4	E10,PO4deficient,WT,PA14,430,,PO4deficient,induced in phosphate limitation [@Hancock:1982if],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,E8,027i,1.E8,porin,OpdH,opdH/PA0757,opdH#PA14_54520::Tn,PA14,NR_36225,7-2	F4,mVBM,tctD#PA14_54500::Tn,PA14,NR_37875,8-1	F6,mVBM,opdH induced when citrate is sole carbon source; opdH is repressed by tctE/tctD (PA0756/PA0757) TCS [@Taylor:2019cn]; deletion of either TCS component causes higher expression in glucose or succinate [@Tamber:2007gh]. TctD is also a repressor of oprP/oprO [@Chevalier:2017ck],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
A1,1,E9,027i,1.E9,secretion,T3SS,exsA/exsD,∆exsA,PA14,1285,,MinS,∆exsD,PA14,1276,,MinS+NTA,"ExsA is T3SS master activator, ExsD is anti-activator; exsA mutants cannot express, while exsD constitutively express T3SS regulon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
A1,1,E10,027i,1.E10,secretion,T3SS,exsA/exsD,∆exsA,PA103,219,,MinS,∆exsD,PA103,408,,MinS+NTA,"ExsA is T3SS master activator, ExsD is anti-activator; exsA mutants cannot express, while exsD constitutively express T3SS regulon",,,,,,,,,,,,,,0.0,0.0,0.0,0.0,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C5,1,E11,027i,1.E11,porin,OprD,oprD/WT,oprD::Tn,PA14,NR_35173,6-4	D9,BM2+ala20mM,WT,PA14,430,,BM2+ala20mM,"frequently lost in infection isolates; loss confers fitness advantage, imipenem resistance; primarily is an amino acid transporter; induced when grown in minimal media w/ arginine, glutamate, or alanine as the sole carbon source [@Ochs:1999jn]",,,,,,,,,,,,-1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,E12,027i,1.E12,c-di-GMP,c-di-GMP,rocR↑/yfiN (tpbB)↑,attB::pAra::rocR,PAK,1644,,ara0.2,attB::pAra::PA1120,PAK,1645,,ara0.2,"c-di-GMP overproduction; rocR is a PDE, yfiN aka tpbB aka PA1120 is a DGC; strains made by Miguel",,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,1.0,1.0,,,,,,,,
,1,F1,027i,1.F1,efflux,MexAB-OprM,efflux/↑mexAB,"∆{mexAB,oprM} +nfxB ∆{mexCD,oprJ} ∆mexJKL ∆mexXY ∆opmH362 ∆{mexEF,oprN}",PAO1 PA0397,1468,,ara0.2,+mexAB+oprM ,PAO1 PA0397,1469,,ara0.2,∆efflux w/ single system complementation in trans; CS = PA0397; [@Chuanchuen:2005gy],,,,,,1.0,1.0,1.0,,0.0,,,,0.0,,,0.0,,0.0,0.0,,,,,,,,,,,,,,0.0,,,,,,,,1.0,0.0,0.0,,,,,,,,,1.0,0.0,0.0,0.0,0.0,,,,,,,,,,,,,,,,,,,
,1,F2,027i,1.F2,efflux,MexCD-OprJ,efflux/↑mexCD,"∆{mexAB,oprM} +nfxB ∆{mexCD,oprJ} ∆mexJKL ∆mexXY ∆opmH362 ∆{mexEF,oprN}",PAO1 PA0397,1468,,ara0.2,+mexCD+oprJ,PAO1 PA0397,1470,,ara0.2,∆efflux w/ single system complementation in trans; CS = PA0397; [@Chuanchuen:2005gy],,,,,,1.0,,1.0,1.0,0.0,1.0,,,0.0,,,0.0,,0.0,0.0,,,,,,,,,,,,,,0.0,,,,,,,,0.0,1.0,0.0,,,,,,,,,0.0,1.0,0.0,0.0,0.0,,,,,,,,,,,,,,,,,,,
,1,F3,027i,1.F3,efflux,MexEF-OprN,efflux/↑mexEF,"∆{mexAB,oprM} +nfxB ∆{mexCD,oprJ} ∆mexJKL ∆mexXY ∆opmH362 ∆{mexEF,oprN}",PAO1 PA0397,1468,,ara0.2,+mexEF+oprN,PAO1 PA0397,1471,,ara0.2,∆efflux w/ single system complementation in trans; CS = PA0397; [@Chuanchuen:2005gy],,,,,,,1.0,1.0,1.0,0.0,,,,0.0,,,0.0,,0.0,0.0,,,,,,,,,,,,,,0.0,,,,,,,,0.0,0.0,1.0,,,,,,,,,0.0,0.0,1.0,0.0,0.0,,,,,,,,,,,,,,,,,,,
,1,F4,027i,1.F4,efflux,MexJK-OprM,efflux/↑mexJK,"∆{mexAB,oprM} +nfxB ∆{mexCD,oprJ} ∆mexJKL ∆mexXY ∆opmH362 ∆{mexEF,oprN}",PAO1 PA0397,1468,,ara0.2,+mexJK+oprM,PAO1 PA0397,1472,,ara0.2,∆efflux w/ single system complementation in trans; CS = PA0397; [@Chuanchuen:2005gy],,,,,,1.0,1.0,0.0,1.0,-1.0,1.0,,,0.0,,,0.0,,0.0,0.0,,,,,,,,,,,,,,0.0,,,,,,,,1.0,0.0,0.0,,,,,,,,,0.0,0.0,0.0,1.0,0.0,,,,,,,,,,,,,,,,,,,
,1,F5,027i,1.F5,efflux,MexXY-OprM,efflux/↑mexXY,"∆{mexAB,oprM} +nfxB ∆{mexCD,oprJ} ∆mexJKL ∆mexXY ∆opmH362 ∆{mexEF,oprN}",PAO1 PA0397,1468,,ara0.2,+mexXY+oprM,PAO1 PA0397,1473,,ara0.2,∆efflux w/ single system complementation in trans; CS = PA0397; [@Chuanchuen:2005gy],,,,,,,1.0,1.0,,1.0,1.0,,,0.0,,,0.0,,0.0,0.0,,,,,,,,,,,,,,0.0,,,,,,,,1.0,0.0,0.0,,,,,,,,,0.0,0.0,0.0,0.0,1.0,,,,,,,,,,,,,,,,,,,
,1,F6,027i,1.F6,efflux,MexXY-OprM,efflux/WT,"∆{mexAB,oprM} +nfxB ∆{mexCD,oprJ} ∆mexJKL ∆mexXY ∆opmH362 ∆{mexEF,oprN}",PAO1 PA0397,1468,,LB,WT,PAO1 Lory,1467,,tet4,tet 4 µg/mL -> ~15x increase in mexXY [@Dean:2003er],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,1.0,0.0,0.0,,,,,,,,,0.0,0.0,0.0,0.0,1.0,,,,,,,,,,,,,,,,,,,
,1,F7,027i,1.F7,efflux,MexEF-OprN,efflux/WT,"∆{mexAB,oprM} +nfxB ∆{mexCD,oprJ} ∆mexJKL ∆mexXY ∆opmH362 ∆{mexEF,oprN}",PAO1 PA0397,1468,,LB,WT,PAO1 Lory,1467,,cam16,chloramphenicol 16 µg/mL -> increased mexEF-oprN expression [@Fetar:2011ih],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,1.0,0.0,1.0,,,,,,,,,0.0,0.0,1.0,0.0,0.0,,,,,,,,,,,,,,,,,,,
F12,1,F8,027i,1.F8,iron,PirA (FepA),pirA/WT,pirA#PA14_52230::Tn,PA14,NR_35992,7-2	B5,M9+chelex,WT,PA14,430,,M9+chelex,ferric enterobactin siderophore receptor; tonB-dependent[@Cornelis:2009dk] [@Ghysels:2005bf],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,
G2,1,F9,027i,1.F9,iron,PhuR,phuR/WT,phuR#PA14_62350::Tn,PA14,NR_53271,13-1	A7,M9+chelex,WT,PA14,430,,M9+chelex,heme uptake receptor Phu [@Minandri:2016ba],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,
G3,1,F10,027i,1.F10,iron,TonB,tonB/WT,tonB::Tn,PA14,NR_32482,5-3	G5,M9+chelex,WT,PA14,430,,M9+chelex,energy transducer and active transport; most iron acquisition systems are TonB-dependent,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,
,1,F11,027i,1.F11,iron,FpvA,fpvA/WT,fpvA::Tn,PA14,NR_43776,10-4	H1,M9+chelex,WT,PA14,430,,M9+chelex,pyoverdine siderophore transporter. [@Cornelis:2009dk] [@Takase:2000ir],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,
,1,F12,027i,1.F12,iron,FptA,fptA/WT,fptA::Tn,PA14,NR_41286,9-4	D5,M9+chelex,WT,PA14,430,,M9+chelex,pyochelin siderophore transporter. [@Cornelis:2009dk] [@Takase:2000ir],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,
,1,G1,027i,1.G1,iron,PfeA,pfeA/WT,pfeA::Tn,PA14,NR_31415,5-1	E9,LB,WT,PA14,430,,LB,ferric enterobactin siderophore receptor; tonB-dependent[@Cornelis:2009dk] [@Takase:2000ir],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,
F9,1,G2,027i,1.G2,c-di-GMP,SCV,wspF/WT,wspF#PA14_16480::Tn,PA14,NR_29257,4-1	C7,,WT,PA14,430,,,"wspF mutant is constitutively c-di-GMP on; wspF mutant has autoaggregative small colony variant (SCV) phenotype [@DArgenio:2002ff]. wspF mutant may have greater phenotypic difference vs. WT in liquid, whereas on surface WT will be c-di-GMP on too. ",,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,-1.0,-1.0,,-1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1,G3,027i,1.G3,c-di-GMP,SCV,WT/wspF,WT,PA14,430,,,wspF#PA14_16480::Tn,PA14,NR_29257,4-1	C7,,see 1-G2 (opposite direction),,,,,,,,,,,,,-1.0,,,,,,,,,,,,,,,,,,,,,,,1.0,1.0,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
D1,1,G4,027i,1.G4,efflux,MexT,mexT,mexT::Tn,PA14,NR_46755,12-1	E6,,WT,PA14,430,,,"MexT inhibits MexAB-OprM transcription, downregulates OprD, downregulates T3SS, and may activate MexEF-OprN [@Li:2015fx] p.374",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.0,,,,,,,,1.0,,1.0,,,-1.0,,,,,,1.0,,1.0,,,,,,,,,,,,,,,,,,,,,
D2,1,G5,027i,1.G5,efflux,MexI,mexI,mexI::Tn,PA14,NR_43615,10-4	F5,,WT,PA14,430,,,component of the MexGHI-OpmD system [@Aendekerk:2002ku],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,
C1,1,G6,027i,1.G6,efflux,MexAB-OprM,oprM/nalC,oprM::Tn,PA14,NR_38915,8-3	D1,,nalC#PA14_16280::Tn,PA14,NR_31143,5-1	B6,,nalC mutants overexpress MexAB-OprM and increase resistance [@Li:2015fx],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,
C2,1,G7,027i,1.G7,efflux,MexAB-OprM,oprM/nalC,oprM::Tn,PA14,NR_38915,8-3	D1,,nalC#PA14_16280::Tn,PA14,NR_31143,5-1	B6,,nalC mutants overexpress MexAB-OprM and increase resistance [@Li:2015fx],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,
C3,1,G8,027i,1.G8,efflux,MexAB-OprM,oprM/nalD,oprM::Tn,PA14,NR_38915,8-3	D1,,nalD#PA14_18080::Tn,PA14,NR_27882,3-2	D1,,NalD inhibits mexAB-oprM transcription,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,
C4,1,G9,027i,1.G9,efflux,MexXY-OprM,oprM/mexZ,oprM::Tn,PA14,NR_38915,8-3	D1,,mexZ#PA14_38380::Tn,PA14,NR_41094,9-3	H8,,"MexZ inhibits mexXY-(oprA) transcription (oprA is only present in PA7-clade, in other strains MexXY-works mostly w/ OprM) [@Li:2015fx]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,
,1,G10,027i,1.G10,efflux,MexCD-OprJ,WT/nfxB,WT,PA14,430,,,nfxB::Tn,PA14,NR_55219,13-4	A11,,NfxB inhibits mexCD-oprJ transcription; nfxB mutants overexpress [@Li:2015fx]. oprJ::Tn mutant from PA14_NR didn't grow,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,
,1,G11,027i,1.G11,efflux,MexJK-OprM,oprM/mexL,oprM::Tn,PA14,NR_38915,8-3	D1,,mexL#PA14_16790::Tn,PA14,NR_48660,13-3	B1,,MexL inhibits mexJK transcription [@Li:2015fx]; not sure how much influence it has on OprM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,
B12,1,G12,027i,1.G12,efflux,MexAB-OprM,(mexAB-oprM) (mexCD-oprJ) mexJKL (mexHI-opmD) opmH/WT,"∆{mexAB,oprM} ∆{mexCD,oprJ} ∆mexJKL ∆{mexHI,opmD} ∆opmH",PAO1 MB5919,1377,,,WT,PAO1 MB5919,1376,,,MexAB-OprM is constitutive [@Adewoye:2002jm],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,0.0,0.0,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,
,1,H1,027i,1.H1,efflux,MexAB-OprM,(mexAB-oprM) (mexCD-oprJ) mexJKL (mexHI-opmD) opmH/WT,"∆{mexAB,oprM} +nfxB ∆{mexCD,oprJ} ∆mexJKL ∆mexXY ∆opmH362 ∆{mexEF,oprN}",PAO1 PA0397,1468,,,WT,PAO1 Lory,1467,,,MexAB-OprM is constitutive [@Adewoye:2002jm],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,0.0,0.0,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,
G5,1,H2,027i,1.H2,fimbrae,CupB5 adhesin,cupB5/WT,cupB5::Tn,PA14,NR_53195,12-4	H9,,WT,PA14,430,,,"atypical T5bSS (two-partner) passenger; cupB3 serves as TpsA component, sorta... [@Ruer:2008jk] [@Filloux:2011dl]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,
,1,H3,027i,1.H3,fimbrae,CupA fimbrae,mvaT/cupA3,cupA3::Tn,PA14,NR_30364,4-3	F12,,mvaT::Tn,,NR_34492,6-3	B7,,mvaT is a negative regulator of cupA gene cluster but not cupB or cupC [@Vallet:2004id],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,
,1,H4,027i,1.H4,fimbrae,CupB fimbrae,cupB3/rocR,cupB3::Tn,PA14,NR_55040,13-3	G11,,rocR#PA14_12810::Tn,PA14,NR_28357,14-4	G4,,"cupB3, the usher component, forms a pore in the outer membrane; negatively regulated by rocR [@Mikkelsen:2011ika]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,
,1,H5,027i,1.H5,fimbrae,CupB fimbrae,cupB3/rocR,cupB3::Tn,PA14,NR_55040,13-3	G11,,rocR#PA14_12810::Tn,PA14,NR_28357,12-1	F5,,"cupB3, the usher component, forms a pore in the outer membrane; negatively regulated by rocR [@Mikkelsen:2011ika]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,
,1,H6,027i,1.H6,fimbrae,CupC fimbrae,cupC3/rocR,cupC3::Tn,PA14,NR_56031,14-1	B3,,rocR#PA14_12810::Tn,PA14,NR_28357,14-4	G4,,"cupC3, the usher component, forms a pore in the outer membrane; negatively regulated by rocR [@Mikkelsen:2011ika]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,
,1,H7,027i,1.H7,fimbrae,CupC fimbrae,cupC3/rocR,cupC3::Tn,PA14,NR_33483,15-1	E4,,rocR#PA14_12810::Tn,PA14,NR_28357,12-1	F5,,"cupC3, the usher component, forms a pore in the outer membrane; negatively regulated by rocR [@Mikkelsen:2011ika]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,
,1,H8,027i,1.H8,fimbrae,CupD fimbrae,cupD3/pvrR,cupD3#PA14_59735::Tn,PA14,NR_53232,15-1	G10,,pvrR::Tn,PA14,NR_37812,8-1	E6,,"unlike other cup fimbrae, CupD is found only in PA14 and PA7; pvrR is negative regulator (PvrRS TCS). [@Mikkelsen:2011ika]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,
,1,H9,027i,1.H9,fimbrae,CupD fimbrae,cupD3/pvrR,cupD3#PA14_59735::Tn,PA14,NR_23406,1-1	F5,,pvrR::Tn,PA14,NR_37610,15-2	A11,,"unlike other cup fimbrae, CupD is found only in PA14 and PA7; pvrR is negative regulator (PvrRS TCS). [@Mikkelsen:2011ika]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,
B8,1,H10,027i,1.H10,general,Pa,SA113/WT,,SA113,,,,WT,PA14,430,,,,,,,,,,,,,,,,,1.0,0.0,1.0,1.0,1.0,1.0,1.0,,,,1.0,,,,,,,,,,1.0,0.0,1.0,0.0,,,,,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,,,,,,,,1.0,,,,1.0,0.0,0.0,0.0,0.0,,,0.0,1.0,,,1.0
B8,1,H11,027i,1.H11,general,Pa,SA113/WT,,SA113,,,,WT,PA14,430,,,,,,,,,,,,,,,,,1.0,0.0,1.0,1.0,1.0,1.0,1.0,,,,1.0,,,,,,,,,,1.0,0.0,1.0,0.0,,,,,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,,,,,,,,1.0,,,,1.0,0.0,0.0,0.0,0.0,,,0.0,1.0,,,1.0
B8,1,H12,027i,1.H12,general,Pa,SA113/WT,,SA113,,,,WT,PA14,430,,,,,,,,,,,,,,,,,1.0,0.0,1.0,1.0,1.0,1.0,1.0,,,,1.0,,,,,,,,,,1.0,0.0,1.0,0.0,,,,,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,,,,,,,,1.0,,,,1.0,0.0,0.0,0.0,0.0,,,0.0,1.0,,,1.0
B7,2,A1,027i,2.A1,general,Pa,SA113/WT,,SA113,,,,WT,PAK,517,,,,,,,,,,,,,,,,,1.0,1.0,0.0,1.0,1.0,1.0,1.0,,,,1.0,,,,,,,,,,1.0,0.0,1.0,1.0,,,,,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,,,,,,,,1.0,,,,1.0,0.0,0.0,0.0,0.0,,,1.0,1.0,,,1.0
,2,A2,027i,2.A2,general,Pa,SA113/WT,,SA113,,,,WT,PAO1,220,,,,,,,,,,,,,,,,,1.0,0.0,1.0,1.0,1.0,1.0,1.0,,,,1.0,,,,,,,,,,1.0,0.0,1.0,1.0,,,,,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,,,,,,,,1.0,,,,1.0,0.0,0.0,0.0,0.0,,,1.0,1.0,,,1.0
,2,A3,027i,2.A3,general,Pa,SA113/WT,,SA113,,,,WT,PA103,209,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,1.0,1.0,1.0,,,,1.0,,,,,,,,,,1.0,0.0,0.0,0.0,,,,,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,,,,,,,,1.0,,,,1.0,0.0,0.0,0.0,0.0,,,1.0,1.0,,,1.0
D9,2,A4,027i,2.A4,LPS,LPS CoreOS [galU],galU/WT,galU::Tn,PA14,NR_52640,12-3	H7,,WT,PA14,430,,,"galU mutants have a characteristic truncated LPS outer core oligosaccharide (core OS) [@Kocincova:2011ez], which in turn is not capped by O-antigen (rough LPS) [@Priebe:2004bw]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,1.0,
D10,2,A5,027i,2.A5,LPS,LPS OSA,waaL/WT,waaL#PA14_66100::Tn,PA14,NR_31296,No grow 2	H2,,WT,PA14,430,,,O-specific antigen-lipid A ligase. Mutants produce only uncapped LPS = Lipid A::Core OS [@Lam:2011gm],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,
D11,2,A6,027i,2.A6,LPS,LPS OSA [Short-Very Long],wzy/WT,wzy::aacC1,PA103,433,,,WT,PA103,209,,,"O-specific antigen polymerase. wzy mutants produce only OSA-capped LPS only with very short polysaccharides (one monomer, aka ""Core+1"") = Lipid A::Core OS::OSA[Core+1]  [@Lam:2011gm]",,,,,,,,,,,,,,0.0,0.0,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,
D12,2,A7,027i,2.A7,LPS,LPS OSA [Long],wzz/WT,wzz::Tn,PA14,NR_33590,6-1	F2,,WT,PA14,430,,,O-specific antigen chain length regulator; wzz mutants do not produce intermediate-length OSA; = Lipid A::Core OS::OSA[Low MW or High MW] [@Lam:2011gm],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,
E1,2,A8,027i,2.A8,LPS,LPS OSA,wbpL/WT,wbpL::Tn,PA14,NR_35855,14-3	A10,,WT,PA14,430,,,O-specific antigen glycosyltransferrase; mutants produce only uncapped LPS = Lipid A::Core OS [@Lam:2011gm],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,
E2,2,A9,027i,2.A9,LPS,LPS OSA,wbpM/WT,wbpM::Tn,PA14,NR_28941,3-4	E4,,WT,PA14,430,,,O-specific antigen sugar epimerase; mutants produce only uncapped LPS = Lipid A::Core OS [@Belanger:1999bja] [@Burrows:1996im] [@Lam:2011gm],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,
,2,A10,027i,2.A10,LPS,LPS palmitoyl-lipid A,pagP/WT,pagP#PA14_46900::Tn,PA14,NR_44264,11-1	F5,,WT,PA14,430,,,PagP transfers palmitate from OM lipids to lipid A [@Thaipisuttikul:2014ca],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,
,2,A11,027i,2.A11,LPS,LPS,lptD/WT,lptD#PA14_07770::Tn,PA14,NR_36177,7-2	E9,,WT,PA14,430,,,LptD is a beta-barrel transporter responsible for the final step of LPS transport and delivery to the OM; mutation leads to general membrane permeation [@Balibar:2016iaa],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0
,2,A12,027i,2.A12,LPS,LPS,lptD/WT,lptD#PA14_07770::Tn,PA14,NR_38436,8-2	F2,,WT,PA14,430,,,LptD is a beta-barrel transporter responsible for the final step of LPS transport and delivery to the OM; mutation leads to general membrane permeation [@Balibar:2016iaa],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0
E3,2,B1,027i,2.B1,LPS,LPS Lipid A [L-Ara4N],WT/phoQ,WT,PA14,430,,,phoQ::Tn,PA14,NR_33095,5-4	G3,,see 2-D3,-1.0,,-1.0,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,1.0,,,,,
A11,2,B2,027i,2.B2,motility,flagellum,WT/fleQ_PA103(V240G),WT,PA103,209,,,fleQ>fleQ(V240G),PA103,979,,,PA103 WT is aflagellate; 1aa mutation in fleQ restores flagellum in PA103 [@Jain:2014bi],,,,,,,,,,,,,,1.0,1.0,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
A12,2,B3,027i,2.B3,motility,flagellum,fleQ/WT,fleQ::Tn,PA14,NR_24554,1-3	H6,,WT,PA14,430,,,FleQ is master transcription factor [@Jyot:2002fg] regulating flagellum gene expression,,,,,,,,,,,,,,1.0,,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
B1,2,B4,027i,2.B4,motility,flagellum,flhA/fleN,∆flhA,PAK,822,,,∆fleN,PAK,1299,,,"FlhA is the secretion gatekeeper for the flagellar T3SS; necessary for secretion of rod components. OM components of flagellar hook-basal body do not appear to assemble in absence of rod, so flhA mutants lack all flagellar omponents",,,,,,,,,,,,,,1.0,1.0,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
B3,2,B5,027i,2.B5,motility,flagellum,fleQ/fleN,fleQ::Tn,PA14,NR_24554,1-3	H6,,fleN::Tn,PA14,NR_25096,1-4	G10,,Aflagellate strains (∆fleQ) tend to overexpress T4P in liquid,,,,,,,,,,,,,,1.0,,1.0,1.0,,-1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
B9,2,B6,027i,2.B6,motility,flagellum,pilQ/WT,∆pilQ,PAO1,1052,,,WT,PAO1,220,,,,,,,,,,,,,,,,,,,,,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
B10,2,B7,027i,2.B7,motility,T4P,pilQ/PA103_fleQ,∆pilQ,PA103,1053,,,WT,PA103,209,,,PA103 WT is aflagellate due to mutation in fleQ [@Jain:2014bi],,,,,,,,,,,,,,-1.0,,-1.0,,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
B11,2,B8,027i,2.B8,motility,T4P/flagellum,pilQ/fleQ,pilQ::Tn,PA14,NR_41699,10-1	D5,,fleQ::Tn,PA14,NR_24554,1-3	H6,,Aflagellate strains (∆fleQ) tend to overexpress T4P in liquid,,,,,,,,,,,,,,-1.0,,-1.0,-1.0,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,B9,027i,2.B9,motility,flagellin,fliC/WT,∆fliC::TcR,PAK,388,,,WT,PAK,517,,,"PAK, PA103 have a-type flagellin, while PAO1 and PA14 have b-type flagellin [@Spangenberg:1996ju] [@Brimer:1998tt] [@Jain:2014bi]",,,,,,,,,,,,,,1.0,1.0,-1.0,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,B10,027i,2.B10,motility,flagellin,fliC/WT,∆fliC::TcR,PAO1,298,,,WT,PAO1,220,,,,,,,,,,,,,,,,,1.0,-1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,B11,027i,2.B11,motility,flagellar hook/basal body,flhA/fleN fliC,∆flhA,PAK,822,,,∆fliC ∆fleN,PAK,1330,,,"∆flhA makes no flagellar apparatus, ∆fleN ∆fliC overepresses flagellar hook/basal body but make no filament",,,,,,,,,,,,,,0.0,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,B12,027i,2.B12,motility,flagellar hook/basal body,flhA/fleN fliC,∆flhA,PAK,822,,,∆fliC ∆fleN,PAK,1330,,,"∆flhA makes no flagellar apparatus, ∆fleN ∆fliC overepresses flagellar hook/basal body but make no filament",,,,,,,,,,,,,,0.0,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,C1,027i,2.C1,motility,flagellar hook/basal body,flhA/fleN fliC,∆flhA,PAK,822,,,∆fliC ∆fleN,PAK,1330,,,"∆flhA makes no flagellar apparatus, ∆fleN ∆fliC overepresses flagellar hook/basal body but make no filament",,,,,,,,,,,,,,0.0,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,C2,027i,2.C2,motility,flagellin,fliC pilA/pilA,∆fliC ∆pilA,PAO1,501,,,∆pilA,PAO1,311,,,,,,,,,,,,,,,,,1.0,,1.0,,,-1.0,,,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C6,2,C3,027i,2.C3,porin,OprL,oprL/WT,oprL::Tn,PA14,NR_24047,1-3	A7,,WT,PA14,430,,,Peptidoglycan-associated lipoprotein (PAL) [@Lim:1997hv]. Has homology to OprF [@Chevalier:2017ck].,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C7,2,C4,027i,2.C4,porin,OprF,oprF,oprF::Tn,PA14,NR_23102,14-4	A2,,WT,PA14,430,,,Structural porin with numerous functions [@Chevalier:2017ck].,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,
C8,2,C5,027i,2.C5,porin,OprG,oprG,oprG::Tn,PA14,NR_41551,10-1	A4,,WT,PA14,430,,,iron uptake porin? [@Chevalier:2017ck],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,C6,027i,2.C6,porin,OprF,oprF/oprD,oprF::Tn,PA14,NR_23102,14-4	A2,,oprD::Tn,PA14,NR_35173,6-4	D9,,"Structural porin with numerous functions [@Chevalier:2017ck]. oprF, oprG, and oprQ are expressed  ~10x higher in PA14 oprD mutant background than WT [@Chevalier:2017cka], [@Skurnik:2013ja]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,C7,027i,2.C7,porin,OprH,oprH/WT,oprH::Tn,PA14,NR_24432,1-3	F10,,WT,PA14,430,,,Outer membrane stabilization porin. [@Chevalier:2017ck],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,
,2,C8,027i,2.C8,porin,OprH/LPS Lipid A [L-Ara4N],oprH/phoQ,oprH::Tn,PA14,NR_24432,1-3	F10,,phoQ::Tn,PA14,NR_33095,5-4	G3,,"Outer membrane stabilization porin. [@Chevalier:2017ck] oprH is negatively regulated by PhoPQ; phoP deletions have lower oprH expression while phoQ deletions have constitutive oprH expression [@Macfarlane:1999fg], in addition to colistin resistance [@Miller:2011ht]",-1.0,,-1.0,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,1.0,1.0,,,,,
,2,C9,027i,2.C9,porin,OprB,oprB/gltR,oprB::Tn,PA14,NR_37924,8-1	F12,,gltR::Tn,PA14,NR_34039,6-2	D3,,"Glucose uptake porin. GltR is a negative regulator of oprB operon, as well as ToxA [@Chevalier:2017cka]",,,,,,,,,,,,,,,,,,,,,,,,,-1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,
G4,2,C10,027i,2.C10,regulator,pleotropic,ampC,ampC::Tn,PA14,NR_46815,12-1	E12,,WT,PA14,430,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
A3,2,C11,027i,2.C11,regulator,pleotropic,retS/WT,∆retS#PA103_4856,PA103,47,,,WT,PA103,209,,,"retS mutant should overexpress Pel/Psl and T6SS like a ""chronic"" isolate, downregulating motility and T3SS.",,,,,,,,,,,,,,0.0,0.0,0.0,0.0,,1.0,,,,,,,,,,,,,,,1.0,-1.0,-1.0,-1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
A6,2,C12,027i,2.C12,regulator,pleotropic,WT/retS,WT,PA103,209,,,∆retS#PA103_4856,PA103,47,,,"retS mutant should overexpress Pel/Psl and T6SS like a ""chronic"" isolate, downregulating motility and T3SS.",,,,,,,,,,,,,,0.0,0.0,0.0,0.0,,-1.0,,,,,,,,,,,,,,,-1.0,1.0,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
A9,2,D1,027i,2.D1,regulator,pleotropic,WT/gacS,WT,PA14,430,,,gacS#PA14_52260::Tn,PA14,NR_47013,12-1	G4,,"gacS mutant should be pro-motility, express T3SS, and downregulate Pel/Psl and T6SS",,,,,,,,,,,,,,1.0,,,,,1.0,,,,,,,,,,,,,,,1.0,-1.0,-1.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
A10,2,D2,027i,2.D2,regulator,pleotropic,WT/gacS,WT,PA14,430,,,gacS#PA14_52260::Tn,PA14,NR_47013,12-1	G4,,"gacS mutant should be pro-motility, express T3SS, and downregulate Pel/Psl and T6SS",,,,,,,,,,,,,,1.0,,,,,1.0,,,,,,,,,,,,,,,1.0,-1.0,-1.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,D3,027i,2.D3,regulator,pleotropic,phoP/phoQ,phoP::Tn,PA14,NR_40573,9-3	A3,,phoQ::Tn,PA14,NR_33095,5-4	G3,,"PhoPQ TCS involved in regulating virulence and other bacterial functions. phoQ mutation induces causes addition of L-Ara4N and palmitate to LPS lipid A, conferring polymyxin B and colistin resistance [@Miller:2011ht] [@Gellatly:2012bh]; upregulation of structural porin OprH [@Chevalier:2017ck] [@Macfarlane:1999fg]; impaired cytotoxicity, twitching motility, and biofilm formation; and transcriptional changes in numerous other regulators (↑ algU, ↓ fhp ) [@Gooderham:2009ej]",-1.0,,-1.0,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,1.0,1.0,,,,,
,2,D4,027i,2.D4,regulator,pleotropic,WT/phoQ,WT,PA14,430,,,phoQ::Tn,PA14,NR_33095,5-4	G3,,see 2-D3,-1.0,,-1.0,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,1.0,,,,,
,2,D5,027i,2.D5,regulator,pleotropic,phoQ/WT,phoQ::Tn,PA14,NR_33095,5-4	G3,,WT,PA14,430,,,see 2-D3,1.0,,1.0,,-1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.0,-1.0,,,,,
E5,2,D6,027i,2.D6,regulator,pleotropic,rpoS/WT,rpoS::Tn,PA14,NR_32095,No grow 3	A10,,WT,PA14,430,,,"rpoS encodes the stationary-phase sigma factor σ^s which has an extensive regulon [@Schulz:2015cm]; deletion mutant transcriptional changes: ↑ genes involved in nitrate metabolism, rsmY, fpvA, phenazine biosynthesis, ↓ genes involved in chemotaxis (cheABDWY). RpoS activation decreases alginate and increases PCN [@Sonnleitner:2003jw]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.0,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,
E6,2,D7,027i,2.D7,regulator,pleotropic,WT/rpoS,WT,PA14,430,,,rpoS::Tn,PA14,NR_32095,No grow 3	A10,,see 2-D6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,-1.0,,,,,,,,,,,,,,,,,,,,,,-1.0,,,,,,,,,,,,,
H1,2,D8,027i,2.D8,regulator,??,rbdA,rbdA#PA14_53140::Tn,PA14,NR_41299,10-4	B7,,WT,PA14,430,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
H2,2,D9,027i,2.D9,regulator,pleotropic,pmrA/WT,pmrA::Tn,PA14,NR_48321,12-3	B8,,WT,PA14,430,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.0,,,,,
H3,2,D10,027i,2.D10,regulator,pleotropic,pmrB/WT,pmrB::Tn,PA14,NR_24651,1-4	B5,,WT,PA14,430,,,PmrAB is a TCS; pmrB mutation leads to constitutive activation of system; mutants have Aminoarabinose addition to LPS Lipid A and are polymyxin resistant [@Moskowitz:2004hy],,,,,-1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,
H4,2,D11,027i,2.D11,regulator,pleotropic,envZ (amgS),envZ::Tn,PA14,NR_54624,13-3	C5,,WT,PA14,430,,,AmgRS is a TCS that activates MexXY [@Li:2015fx]; Tn-insertions in amgR and amgS are selected against in tobramycin [@Gallagher:2010jc],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
H6,2,D12,027i,2.D12,regulator,pleotropic,phoP/phoQ,phoP::Tn,PA14,NR_40573,9-3	A3,,phoQ::Tn,PA14,NR_33095,5-4	G3,,see 2-D3,-1.0,,-1.0,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,1.0,1.0,,,,,
H7,2,E1,027i,2.E1,secretion,T6SS,gacA/retS,gacA::Tn(GmR) fliC::TcR ∆pilA,PAO1,Tom#220,,,retS::Tn(GmR) fliC::TcR ∆pilA,PAO1,Tom#223,,,See 1-D12. These strains are from Tn insertions in [@Murray:2008cs]. ,,,,,,,,,,,,,,0.0,,,-1.0,-1.0,0.0,,,,,,,,,,,,,,,-1.0,1.0,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
H8,2,E2,027i,2.E2,regulator,pleotropic,SA113/ladS,,SA113,,,,ladS#PA14_19340::Tn,PA14,NR_29763,4-2	D6,,"LadS antagonizes RetS, downregulating Psl/Psl and upregulating T3SS [@Mikkelsen:2011ika]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
H9,2,E3,027i,2.E3,regulator,pleotropic,hfq/WT,∆hfq,PA103,249,,,WT,PA103,209,,,"Hfq is an RNA chaperone that activates rpoS and regulates hundreds of other genes [@Pusic:2021jw]. hfq mutants have decreased elastase, increased PCN (via rpoS), decreased alginate (via rpoS), loss of swarming motility, and reduced virulence in wax moth infection model  [@Sonnleitner:2003jw]; hfq mutation affects ~300 genes directly, (including ↑ mexGHI, oprD, oprB, opmD, cupA2;  ↓ oprG, lasA, pvdA, pvdS, fptA, rmlC); hfq also affects QS systems by activating RhlI (via RsmY), activating QscR, and activating PqsH [@Sonnleitner:2006fn]",,,,,,,,,,,,,,0.0,0.0,0.0,0.0,,,,,,,,,,,,,-1.0,1.0,,,,,,,,,,1.0,,,,,,-1.0,,,1.0,,-1.0,,,,,,-1.0,,,,1.0,,,,-1.0,,,,,,,,,,
H10,2,E4,027i,2.E4,regulator,pleotropic,WT/hfq,WT,PA103,209,,,∆hfq,PA103,249,,,"Hfq is an RNA chaperone that activates rpoS and regulates hundreds of other genes [@Pusic:2021jw]. hfq mutants have decreased elastase, increased PCN (via rpoS), decreased alginate (via rpoS), loss of swarming motility, and reduced virulence in wax moth infection model  [@Sonnleitner:2003jw]; hfq mutation affects ~300 genes directly, (including ↑ mexGHI, oprD, oprB, opmD, cupA2;  ↓ oprG, lasA, pvdA, pvdS, fptA, rmlC); hfq also affects QS systems by activating RhlI (via RsmY), activating QscR, and activating PqsH [@Sonnleitner:2006fn]",,,,,,,,,,,,,,0.0,0.0,0.0,0.0,,,,,,,,,,,,,1.0,-1.0,,,,,,,,,,-1.0,,,,,,1.0,,,-1.0,,1.0,,,,,,1.0,,,,-1.0,,,,1.0,,,,,,,,,,
H11,2,E5,027i,2.E5,regulator,pleotropic,flhF/flhF-vfr,∆flhF ∆vfr,PAK,1176,,,∆flhF ∆vfr,PAK,1176,,,disregard; this should have been ∆vfr ∆flhF vs ∆flhF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
H12,2,E6,027i,2.E6,regulator,pleotropic,flhF-vfr/flhF,∆flhF,PAK,348,,,∆flhF ∆vfr,PAK,1176,,,"Vfr binds cAMP (homolog to CRP in Ec) and predominantly promotes acute virulence, controlling >200 genes (inc. ↑ T4P, T3SS, T2SS, secreted toxins inc. ToxA, las and rhl QS systems; ↓ fleQ) [@Coggan:2012td]",,,,,,,,,,,,,,1.0,,,1.0,-1.0,-1.0,,,,,-1.0,-1.0,,,,,,,,,-1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C9,2,E7,027i,2.E7,secretion,???,bamB/WT,bamB#PA14_14910::Tn,PA14,NR_40644,9-3	A8,,WT,PA14,430,,,"BamB is a non-essential component of the beta barrel assembly machinery (BAM); Tn-insertions increased susceptibility to vancomycin and rifampicin [@Rundell:2020bq]. This gene only annotated as bamB in PAK (PAKAF_RS05830), but chromosomal locus looks similar in PAO1 and PA14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
C10,2,E8,027i,2.E8,secretion,???,bamC/WT,bamC#PA14_51260::Tn,PA14,NR_38046,8-2	A4,,WT,PA14,430,,,BamC is a non-essential component of the BAM system; Tn-insertions increased susceptibility to vancomycin [@Rundell:2020bq],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,E9,027i,2.E9,secretion,T6SS,WT/mvfR (pqsR),mvfR::Tn,PA14,NR_47015,12-1	G5,,WT,PA14,430,,,PqsR (aka MvfR) is a transcriptional activator that activates the pqsABCDE operon; pqsR mutation eliminates all AQ and Pcn production [@Lee:2015bh]. MvfR inhibits T6SS HSI-I but activates HSI-II and HSI-III [@Chen:2015ih],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,E10,027i,2.E10,secretion,T6SS,gacA/retS,gacA::Tn(GmR) fliC::TcR ∆pilA,PAO1,Tom#220,,,retS::Tn(GmR) fliC::TcR ∆pilA,PAO1,Tom#223,,,See 1-D12. These strains are from Tn insertions in [@Murray:2008cs]. ,,,,,,,,,,,,,,0.0,,,-1.0,-1.0,0.0,,,,,,,,,,,,,,,-1.0,1.0,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,E11,027i,2.E11,secretion,T6SS,gacA/retS,gacA::Tn(GmR) fliC::TcR ∆pilA,PAO1,Tom#220,,,retS::Tn(GmR) fliC::TcR ∆pilA,PAO1,Tom#223,,,See 1-D12. These strains are from Tn insertions in [@Murray:2008cs]. ,,,,,,,,,,,,,,0.0,,,-1.0,-1.0,0.0,,,,,,,,,,,,,,,-1.0,1.0,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
A2,2,E12,027i,2.E12,secretion,T3SS,retS/exsD,∆retS#PA103_4856,PA103,47,,,∆exsD,PA103,408,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,,,,,,,,,,,,,,,,,1.0,-1.0,-1.0,-1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,F1,027i,2.F1,secretion,T2SS sec secretion products,sec/WT,secB::Tn,PA14,NR_46670,12-1	D12,,WT,PA14,430,,,"Sec is one of two (Tat is the other)  IM secretion systems (from cytoplasm to periplasm) that feed T2SS transporters in the OM. SecA is essential, secB deletion abrogates most but not all Sec translocation. ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,F2,027i,2.F2,secretion,T2SS tat secretion products,tatC/WT,tatC::Tn,PA14,NR_54153,13-2	D11,,WT,PA14,430,,,"Tat is the other, Sec-independent IM transporter system (from cytoplasm to periplasm) for T2SS substrates. TatC is essential for all known tat-system translocons [@Voulhoux:2001fz]. Tat repertoire? [@Lewenza:2005cj]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,F3,027i,2.F3,secretion,lon protease,lon/WT,lon::Tn,PA14,NR_29158,4-1	A9,,WT,PA14,430,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,F4,027i,2.F4,secretion,disulfide reductase dependent secretion products,dsbM/WT,dsbM#PA14_00700::Tn,PA14,NR_27274,3-1	B6,,WT,PA14,430,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,F5,027i,2.F5,secretion,bam system secretion products,bamB/WT,bamB#PA14_14910::Tn,PA14,NR_40644,9-3	A8,,WT,PA14,430,,,"BamB is a non-essential component of the beta barrel assembly machinery (BAM) only annotated as bamB in PAK (PAKAF_RS05830), but chromosomal locus looks similar in PAO1 and PA14",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,F6,027i,2.F6,secretion,T1SS Apr,aprF/WT,aprF::Tn,PA14,NR_41032,9-3	G8,,WT,PA14,430,,,AprF is T1SS for alkaline protease AprA [@Filloux:2011dl],,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,F7,027i,2.F7,secretion,T5aSS EstA,estA/WT,estA::Tn,PA14,NR_53827,13-1	H9,,WT,PA14,430,,,EstA C-terminus is a T5aSS autotransporter for lipase EstA [@Filloux:2011dl],,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,F8,027i,2.F8,secretion,T2SS sec secretion products,sec/WT,secB::Tn,PA14,NR_46670,12-1	D12,,WT,PA14,430,,,See 2-F1,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,F9,027i,2.F9,secretion,T5dSS PlpD,plpD/WT,plpD#PA14_20870::Tn,PA14,NR_29037,3-4	G6,,WT,PA14,430,,,"PlpD is an atypical T5aSS autotransporter, w/ features of T5bSS [@Filloux:2011dl]",,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,F10,027i,2.F10,secretion,T5bSS LepA,lepA/WT,lepA::Tn,PA14,NR_38761,8-3	A11,,WT,PA14,430,,,"LepA is the passenger/TpsA component of a T5bSS (two-partner) (TpsB = LepB); LepA is a trypsin-like serine protease, ?eukaryotic cell adhesin  [@Filloux:2011dl]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,F11,027i,2.F11,secretion,T2SS tat secretion products,tatC/WT,tatC::Tn,PA14,NR_54153,13-2	D11,,WT,PA14,430,,,See 2-F2,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,F12,027i,2.F12,secretion,T5bSS LepB,lepB/WT,lepB::Tn,PA14,NR_29869,4-2	F8,,WT,PA14,430,,,LepB is the transporter/TpsB component of a T5bSS (two-partner) (TpsA = LepA) [@Filloux:2011dl],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,G1,027i,2.G1,clinical isolate,,,,SA113,,,,,,AP#1018,,,blood cx isolate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,G2,027i,2.G2,clinical isolate,,,,SA113,,,,,,AP#1030,,,blood cx isolate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,G3,027i,2.G3,clinical isolate,,,,SA113,,,,,,AP#1076,,,blood cx isolate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,G4,027i,2.G4,clinical isolate,,,,SA113,,,,,,AP#1085,,,blood cx isolate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,G5,027i,2.G5,clinical isolate,,,,SA113,,,,,,AP#1089,,,blood cx isolate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,G6,027i,2.G6,clinical isolate,,,,SA113,,,,,,AP#1153,,,blood cx isolate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,G7,027i,2.G7,clinical isolate,,,,SA113,,,,,,AP#1156,,,urine cx from AP#1153,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,G8,027i,2.G8,clinical isolate,,,,SA113,,,,,,AP#1157,,,peritoneal dialysis catheter cx,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,G9,027i,2.G9,clinical isolate,,,,SA113,,,,,,AP#1198,,,sputum cx isolate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,G10,027i,2.G10,clinical isolate,,,,SA113,,,,,,AP#1236,,,trach isolate from AP#1153,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,G11,027i,2.G11,clinical isolate,,,,SA113,,,,,,AP#1264B,,,blood cx isolate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,G12,027i,2.G12,clinical isolate,,,,SA113,,,,,,AP#1247A,,,blood cx isolate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,H1,027i,2.H1,clinical isolate,,,,SA113,,,,,,AP#1321A,,,BAL cx isolate from AP#1198,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,H2,027i,2.H2,clinical isolate,,,,SA113,,,,,,AP#1336A,,,blood cx isolate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,H3,027i,2.H3,clinical isolate,,,,SA113,,,,,,AP#1160,,,blood cx isolate from AP#1157,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,H4,027i,2.H4,clinical isolate,,,,SA113,,,,,,AP#1353,,,chronic sputum isolate from AP#1169,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,H5,027i,2.H5,clinical isolate,,,,SA113,,,,,,AP#1363,,,blood cx isolate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,H6,027i,2.H6,clinical isolate,,,,SA113,,,,,,AP#1364,,,trach isolate from AP#1198,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,H7,027i,2.H7,clinical isolate,,,,SA113,,,,,,AP#1358,,,blood cx isolate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,H8,027i,2.H8,clinical isolate,,,,SA113,,,,,,AP#1377,,,blood cx isolate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,H9,027i,2.H9,clinical isolate,,,,SA113,,,,,,AP#1424,,,blood cx isolate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,H10,027i,2.H10,clinical isolate,,,,SA113,,,,,,AP#1429,,,chronic sputum isolate from AP#1327,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,H11,027i,2.H11,clinical isolate,,,,SA113,,,,,,AP#1469A,,,chronic sputum isolate from AP#1336A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,2,H12,027i,2.H12,clinical isolate,,,,SA113,,,,,,AP#1474,,,blood cx isolate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
